The therapeutic landscape for PCSK9 inhibitors is rapidly evolving; therefore, pharmacists require education on the safety and efficacy of PCSK9 inhibitors for the treatment of hyperlipidemia. This curriculum will assist pharmacists in optimizing hyperlipidemia care, as well as enable them to provide both prescribers and patients with pertinent safety and efficacy data about this class of drugs. Expanding the use of PCSK9 inhibitors is warranted to improve clinical outcomes in patients with hyperlipidemia, and the various activities in this series as well as the video vignettes will highlight key takeaways to use in practice.

Latest news from Pharmacy Times:

BMI, LDL Cholesterol Are Important Metrics in Assessing COVID-19 Risk
Learn More >

Week in Review: Study Shows Substance Use Disorders Possibly Linked to COVID-19
Learn More >

FDA Approves New Treatment for Transthyretin Amyloid Cardiomyopathy
Learn More >

Trending News Today: Young Women Have Low Awareness of Cardiovascular Risks
Learn More >

Study: Daily Aspirin Does Not Reduce Risk of Major Cardiovascular Events
Learn More >

ASCEND Trial: Aspirin Prevents Serious Vascular Events in Diabetes
Learn More >

Study: Daily Aspirin Did Not Reduce Risk of First Heart Attack, Stroke
Learn More >

Trending News Today: Smokers More Likely to Develop Atrial Fibrillation 
Learn More >